姑息性胃切除联合术后化疗评分在腹膜转移的胃癌患者预后评估中的临床意义
《现代肿瘤医学》[ISSN:1672-4992/CN:61-1415/R]
- 期数:
- 2019年10期
- 页码:
- 1778-1782
- 栏目:
- 论著（消化·泌尿系肿瘤）
- 出版日期:
- 2019-04-08
文章信息/Info
- Title:
- The clinical impact of score which was caculated by palliative gastrectomy combined with postoperative chemotherapy in gastric cancer patients with peritoneal metastasis
- Author(s):
- Wang Rui; Wang Yimin; Li Fengke; Gao Jialiang; Han Bangling; Xue Yingwei
- Department of Gastrointestinal Surgery,Harbin Medical University Cancer Hospital,Heilongjiang Harbin 150081，China.
- Keywords:
- gastric carcinoma; peritoneal metastasis; score; prognosis
- 分类号:
- R735.2
- DOI:
- 10.3969/j.issn.1672-4992.2019.10.028
- 文献标识码:
- A
- 摘要:
- 目的：探讨姑息性胃切除联合术后化疗评分在腹膜转移的胃癌患者预后评估中的临床意义。方法：回顾性分析2010年1月至2016年12月7年间收治的287例发生腹膜转移的胃癌患者的临床病理资料。通过χ2检验分析评分与患者临床病理因素间的关系。通过Kaplan-Meier法绘制生存曲线，Log-rank检验比较患者生存率的差异；采用Cox比例风险回归模型对患者进行预后分析。结果：与评分中得分为2分和1分的患者相比，得分为0分的患者肿瘤侵润至T4b 期的患者较少［31%(18/58)比50.8%(63/124)、56.2%(59/105)，P=0.039］。全组患者的中位生存时间仅为8.7月。对患者进行单因素预后分析结果显示，血清白蛋白浓度（≤40 g/L），腹水，腹膜转移范围较大，肿瘤T分期较晚，评分得分较高的患者预后较差（均P＜0.05）。将上述因素纳入Cox多因素分析结果显示：评分［HR（95%CI）：1.384（1.165~1.644），P=0.000］，血清白蛋白浓度［HR（95%CI）：0.759（0.593~0.971），P=0.028］，肿瘤T分期［HR（95%CI）：1.493（1.216~1.832），P=0.000］是患者预后的独立危险因素。结论：评分对于胃癌伴腹膜转移患者的预后生存评估具有重要的临床意义。
- Abstract:
- Objective:To evaluate clinical value of score in gastric cancer patients with peritoneal metastasis.Methods:The retrospective research enrolled 287 patients with gastric cancer who were affirmed peritoneal metastasis through operation from January 2010 to December 2016.The categorical variables were tested by Chi-square.Survival analysis was analyzed by Kaplan-Meier method and Log-rank test was utilized to compare the survival difference.The prognosis of the patients was peformed by univariate and multivariate Cox proportional hazards regression model.Results:Compared with the patients with scores of 2 and 1 in the score,the patients with T4b staging in 0 score were fewer［31%(18/58) to 50.8%(63/124),56.2%(59/105)，P=0.039］.The median survival time for all patients was 8.7 months.Univariate analysis revealed that,lower serum albumin level (≤40 g/L)，ascites，larger range of peritoneal metastasis，more late T staging，higher scores were positively associated with poor prognosis (all P＜0.05).Multivariate analysis demonstarted that score ［HR(95%CI):1.384(1.165~1.644),P=0.000］,serum albumin level ［HR(95%CI):0.759(0.593~0.971),P=0.028］,T staging［HR(95%CI):1.493(1.216~1.832),P=0.000］ were independent risk factors for the patients with peritoneal metastasis.Conclusion:The score can act as a predictor of prognosis for gastric cancer patients with peritoneal metastasis.
参考文献/References
［1］ Chen W,Zheng R,Baade PD,et al.Cancer statistics in China,2015 ［J］.Ca Cancer J Clin,2016,66(2):115-132. ［2］ Liang H.Prevention of surgery-related complications of D2+ lymphadenectomy for gastric cancer［J］.Chin J Gastrointest Surg,2017,20(2):140-143.［梁寒.胃癌扩大淋巴结清扫的根治手术相关并发症及其预防［J］.中华胃肠外科杂志,2017,20(2):140-143.］ ［3］ Broll R,Weschta M,Windhoevel U,et al.Prognostic significance of free gastrointestinal tumor cells in peritoneal lavage detected by immunocytochemistry and polymerase chain reaction［J］.Langenbeck's Archives of Surgery,2001,386(4):285-292. ［4］ Yang K,Liu K,Zhang WH,et al.The value of palliative gastrectomy for gastric cancer patients with intraoperatively proven peritoneal seeding［J］.Medicine,2015,94(27):e1051. ［5］ Hamamoto Y.Complications in advanced or recurrent gastric cancer patients with peritoneal metastasis during and after palliative systemic chemotherapy［J］.Mol Clin Oncol,2015,3(3):539-542. ［6］ Ishigami H,Yamaguchi H,Yamashita H,et al.Surgery after intraperitoneal and systemic chemotherapy for gastric cancer with peritoneal metastasis or positive peritoneal cytology findings［J］.Gastric Cancer,2016,20(Suppl 1):1-7. ［7］ Cho H,Ryu MH,Kim KP,et al.Phase I/II study of a combination of capecitabine,cisplatin,and intraperitoneal docetaxel (XP ID) in advanced gastric cancer patients with peritoneal metastasis［J］.Gastric Cancer:Official Journal of the International Gastric Cancer Association & the Japanese Gastric Cancer Association,2017,20(6):1-8. ［8］ Kono K,Yong WP,Okayama H,et al.Intraperitoneal chemotherapy for gastric cancer with peritoneal disease:experience from Singapore and Japan［J］.Gastric Cancer:Official Journal of the International Gastric Cancer Association & the Japanese Gastric Cancer Association,2016,20(Suppl 1):1-6. ［9］ Shimada Y.JGCA (The Japan Gastric Cancer Association).Gastric cancer treatment guidelines［J］.Japanese Journal of Clinical Oncology,2004,34(1):58. ［10］ Japanese Society of Gastric Cancer.Gastric cancer management regulation［M］.14th edition.Tokyo:Jinyuan Publishing,2010:57-61.［日本胃癌学会編.胃癌取扱い規約［M］.14版.东京:金原出版,2010:57-61.］ ［11］ Japanese Gastric Cancer Association.Japanese classification of gastric carcinoma:3rd English edition［J］.Gastric Cancer,2011,14(2):101-112. ［12］ Edge SB,Compton CC.The American Joint Committe on Cancer:the 7th edition of the AJCC cancer staging manunal and the future of TNM［J］.Ann Surg Oncol,2010,17(6):1471-1474. ［13］ Japanese Research Society for Gastric Cancer (JRSGC).Japanese classification of gastric carcinoma［J］.Tokyo,1995:64-67. ［14］ Sugarbaker PH,Yonemura Y.Clinical pathway for the management of resectable gastric cancer with peritoneal seeding:Best palliation with a ray of hope for cure［J］.Oncology,2000,58(2):96-107. ［15］ Baltogiannis G,Katsios C.Predictive factors for improving survival after gastrectomy in gastric cancer patients with peritoneal carcinomatosis［J］.World Journal of Surgery,2010,34(9):2267. ［16］ D'Angelica M,Gonen M,Brennan MF,et al.Patterns of initial recurrence in completely resected gastric adenocarcinoma［J］.Annals of Surgery,2004,240(5):808-816. ［17］ Arto Kokkola MD,Johanna Louhimo MD,Pauli Puolakkainen MD.Does non-curative gastrectomy improve survival in patients with metastatic gastric cancer［J］?Journal of Surgical Oncology,2012,106(2):193-196. ［18］ Li S,Lan X,Gao H,et al.Addition of peritonectomy to gastrectomy can predict good prognosis of gastric adenocarcinoma patients with intraoperatively proven single P1/P2 carcinomatosis［J］.Tumour Biol,2017,39(6):101042831769756. ［19］ Wen Lei，Yang Hainan，Xu Longwen，et al.Cytoreductive surgery plus hyperthermic intraperitoneal chemotherapy for peritoneal carcinomatosis from gastric cancer：A systematic review［J］.Modern Oncology,2017，25（11）：1752-1757.［文磊,杨海南,徐龙文,等.细胞减灭术联合腹腔热灌注化疗治疗胃癌腹膜转移的系统评价［J］.现代肿瘤医学，2017，25（11）：1752-1757.］ ［20］ Cheong JH,Yang HK,Kim H,et al.Predictive test for chemotherapy response in resectable gastric cancer:A multi-cohort,retrospective analysis［J］.Lancet Oncology,2018,19(5):629-638. ［21］ Mcmillan DC.Systemic inflammation,nutritional status and survival in patients with cancer［J］.Curr Opin Clin Nutr Metab Care,2009,12(3):223-226. ［22］ Li C,Ying Y,Zhu L,et al.Systemic immune-inflammation index as a useful prognostic indicator predicts survival in patients with advanced gastric cancer treated with neoadjuvant chemotherapy［J］.Cancer Management & Research,2017,9:849-867. ［23］ Kang SC,Kim HI,Min GK.Low serum albumin level,male sex,and total gastrectomy are risk factors of severe postoperative complications in elderly gastric cancer patients［J］.Journal of Gastric Cancer,2016,16(1):43-50. ［24］ Saito H,Kono Y,Murakami Y,et al.Postoperative serum albumin is a potential prognostic factor for older patients with gastric cancer［J］.Yonago Acta Medica,2018,61(1):72. ［25］ Liu ZJ,Ge XL,Ai SC,et al.Postoperative decrease of serum albumin predicts short-term complications in patients undergoing gastric cancer resection［J］.World Journal of Gastroenterology,2017,23(27):4978-4985. ［26］ Chen F,Yin S,Niu L,et al.Expression of the chemokine receptor CXCR3 correlates with dendritic cell recruitment and prognosis in gastric cancer［J］.Genetic Testing & Molecular Biomarkers,2018,22(1):35. ［27］ Haraguchi N,Arigami T,Uenosono Y,et al.Clinical significance of primary tumor score determined by tumor depth and size in patients with resectable gastric cancer［J］.Oncotarget,2018,9(9):8512-8520. ［28］ Deng J,Zhang R,Pan Y,et al.Tumor size as a recommendable variable for accuracy of the prognostic prediction of gastric cancer:A retrospective analysis of 1 521 patients［J］.Annals of Surgical Oncology,2015,22(2):565-572.
备注/Memo
- 备注/Memo:
- 哈尔滨市科技局应用技术研究与开发项目(编号：2017RAXXJ054);哈尔滨医科大学附属肿瘤医院资助项目（编号：Nn10PY2017-03）
